IN-007
COVID-19 (SARS-CoV-2)
PreclinicalActive
Key Facts
About Inhalon Biopharma
Inhalon Biopharma is pioneering a novel inhaled antibody platform that leverages 'muco-trapping' technology to treat acute respiratory infections directly in the lung. Founded in 2016 and based in San Diego, the private company has advanced its lead candidate, IN-006 for COVID-19, into Phase 1b studies and secured significant non-dilutive grant funding from U.S. government agencies. With a focus on enabling at-home, test-to-treat models, Inhalon aims to address a major unmet need in respiratory care by developing fast-acting, locally delivered therapeutics.
View full company profileTherapeutic Areas
Other COVID-19 (SARS-CoV-2) Drugs
| Drug | Company | Phase |
|---|---|---|
| IN-006 | Inhalon Biopharma | Phase 1b |
| FINVAC COVID-19 | Rokote Laboratories | Phase 1 |
| SAB-185 | SAB Biotherapeutics | Phase 2/3 |